Meanwhile, Ripk3 inhibitors have the potential to be used in combination with other therapeutic agents for ALI, such as anti-inflammatory drugs and antioxidant drugs, with a view to playing a better role in the treatment of ALI. Here, RIPK3 is linked to acute respiratory distress syndrome.